TCRT News & Events

Alaunos Therapeutics announced early data from two non-Good Laboratory Practice diet-induced obesity mouse studies evaluating ALN1003, the company's lead small-molecule drug candidate for treating obesity and related conditions, such as metabolic dysfunction-associated steatotic liver disease. ALN1003 is an oral small-molecule drug being developed for a non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. We conducted two separate studies using a standard diet-induced obesity mouse model in male C57BL/6 mice maintained on a high-fat diet. Highlights from these studies include dose-dependent body weight loss with favorable body composition changes, reductions in liver weight, decreases in liver injury enzymes and other liver-related biomarker, and improvement in metabolic biomarkers. Collectively, these findings suggest encouraging metabolic effects of ALN1003 in the DIO model.

Alaunos Therapeutics entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of 610,399 shares of common stock at a purchase price of $3.36 per share in a registered direct offering on June 20, 2025 based on the 5-day average Nasdaq official closing price. The aggregate gross proceeds to the Company of this offering are expected to be approximately $2.0 million, before deducting the offering expenses payable by the Company. The Company currently intends to use the net proceeds of approximately $1.9 million from the offering for its obesity program and general corporate purposes. The transaction is expected to close on or about June 24, 2025, subject to the satisfaction of customary closing conditions.